Idiopathic Granulomatous Mastitis Combination Therapy
Launched by BASKENT UNIVERSITY · May 3, 2022
Trial Information
Current as of July 21, 2025
Unknown status
Keywords
ClinConnect Summary
AIM:
Primary: The effect of the combination of excision and single dose intraoperative steroid administration to the cavity on the shortening of the recovery period in Idiopathic Granulomatous Mastitis.
Secondary: Comparison of the side effects and the relationship between the treatment method and the serum cortisol level in patients treated with intralesional steroid + low dose oral steroid and topical steroid
THE WORK PLAN:
A prospective registry study was designed to compare the effectiveness of the combination of intralesional steroid administration used in the treatment of IGM + lo...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients diagnosed with IGM histopathologically
- • Patients in groups A, B and C according to clinical classification
- • Ultrasonographically; Patients with leaf-like hypoechoic type, localized abscess type, and localized hypoechoic mass type mastitis
- Exclusion Criteria:
- • Patients diagnosed with tumor after biopsy
- • Those with TB PCR (+)
- • Presence of clinically widespread abscess and cellulite (group D patients)
- • Ultrasonographically; diffuse diffuse type
- • Pregnancy
- • Breastfeeding period
About Baskent University
Baskent University is a distinguished academic and research institution dedicated to advancing healthcare through innovative clinical trials and studies. With a strong emphasis on evidence-based medicine, the university collaborates with a network of healthcare professionals and researchers to design and implement rigorous clinical research that aims to improve patient outcomes. Baskent University is committed to adhering to the highest ethical standards and regulatory guidelines, ensuring the integrity and reliability of its research initiatives while fostering a collaborative environment that promotes scientific discovery and education.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Adana, Yuregir, Turkey
Patients applied
Trial Officials
Ozgur Aytac, MD
Study Director
Baskent University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials